The first and only FDA-approved CD22-directed therapy developed for the treatment of adult patients with relapsed/refractory hairy cell leukemia (HCL) who have received two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)
REMISSION ACCOMPLISHED WITH LUMOXITI
Remission refers to complete response (CR), as confirmed by clearing of the bone marrow of HCL cells.* In a large clinical study of 80 adult patients with relapsed/refractory HCL, 41% (33/80) achieved CR.1
*CR defined as clearing of the bone marrow of hairy cells by routine Hematoxylin & Eosin stain, radiologic resolution of pre-existing lymphadenopathy and/or organomegaly, and hematologic remission.